The company's focus is on developing first-in-class therapeutics for unmet medical needs by targeting the underlying pathologies of thrombosis and type one diabetes. Their approach is based on a deep understanding of the molecular mechanisms of these diseases, which they believe will lead to new treatment paradigms and better outcomes for patients. Specifically, Veralox is developing small molecule therapeutics designed to target heparin-induced thrombocytopenia and thrombosis, with the goal of providing complete recovery for patients with diabetes.